Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-11-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第四届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 健帆生物科技集团股份有限公司 regarding investment agreements and the establishment of a wholly-owned subsidiary. It includes details of meeting attendance, voting results, and references to other announcements on the official disclosure website. The document is short (1087 characters) and primarily serves as an official announcement of board decisions rather than a full report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive meeting resolutions. The content fits best under Board/Management Information (MANG) as it relates to corporate governance decisions and board resolutions.
2020-11-11 Chinese
第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 健帆生物科技集团股份有限公司 on November 11, 2020. It details the attendance, the agenda items discussed, and the voting results on investment agreements and the establishment of a wholly-owned subsidiary. There is no financial data, earnings information, or detailed report content. The document is not a full report but an announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2020-11-11 Chinese
关于签订生物材料项目投资协议书及对外投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about signing an investment agreement and establishing a wholly-owned subsidiary for a biological materials project. It details the investment amount, project scope, approvals by the board and supervisory committee, and risks involved. There are no financial statements or detailed financial performance data. The document is a corporate announcement about a capital investment and subsidiary formation, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through investment and subsidiary establishment. The document length is 3365 characters, which is consistent with an announcement rather than a full report.
2020-11-11 Chinese
关于《关于健帆生物科技集团股份有限公司申请向不特定对象发行可转换公司债券的审核中心意见落实函》的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an accounting firm (致同会计师事务所) to the Shenzhen Stock Exchange regarding a company's application to issue convertible bonds to unspecified investors. It includes extensive financial data, market analysis, production capacity utilization, industry comparisons, and risk disclosures related to the company's planned capital raising project. The document contains audit-related opinions and verification of financial and operational data but is not a full annual or interim report. It is not a simple announcement or certification but a comprehensive audit-related response focusing on the reasonableness and feasibility of the new production capacity in relation to market demand and company performance. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related document with accounting and financial verification content, distinct from a full Annual Report or Interim Report. The document length (13,406 characters) and content depth support this classification with high confidence. 9M 2020
2020-11-04 Chinese
关于公司向不特定对象发行可转换公司债券的审核中心意见落实函的回复公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the company's response to a regulatory review letter from the Shenzhen Stock Exchange about its application to issue convertible bonds to unspecified investors. It discusses the submission of reply materials and the ongoing approval process, emphasizing the uncertainty and the company's commitment to disclose further information. The document is short (725 characters) and serves as an update on a financing activity rather than the actual issuance or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to capital raising activities and regulatory review thereof.
2020-11-04 Chinese
公司与中航证券有限公司关于申请向不特定对象发行可转换公司债券的审核中心意见落实函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response letter from a company (健帆生物科技集团股份有限公司) and its underwriters and auditors to the Shenzhen Stock Exchange regarding the application for issuing convertible bonds to unspecified investors. It includes extensive discussion on the company's production capacity, market analysis, industry competition, and risk disclosures related to the proposed capital raising project. The document references a "募集说明书" (offering prospectus) and addresses regulatory review comments, indicating it is part of a regulatory filing process related to capital raising. The content focuses on the company's financing activities and the justification for the new capital raising project, rather than being a full financial report, earnings release, or management discussion. It is not a report publication announcement or a certification letter but a substantive regulatory response document. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2020-11-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.